Skip to Content

'
Nina D. Shah, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 423
Houston, TX 77030
Room Number: FC5.3030
Phone: 713.794.5745
Fax: 713.794.4902
Email: nshah@mdanderson.org

Education & Training

Degree-Granting Education

2002 New York University School of Medicine, New York, NY, MD, Doctorate of Medicine
1998 Harvard University, Cambridge, MA, BA, Psychology & Biology (Cognitive Neuroscience)

Board Certifications

2005 American Board of Internal Medicine - Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia. e-Pub 2/2011. PMID: 21350559.
2. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That is Reversed with IL-2 Exvivo Expansion. J Immunother 33(7):684-696, 9/2010. PMID: 20664358.
3. Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, Shah N, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJ. CD3+ and/or CD14+ depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34+ cell yields. Bone Marrow Transplant 45(6):1000-1007, 6/2010. e-Pub 10/2009. PMID: 19838220.
4. Shah N, Lonial S. Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010:310-3, 2010. PMID: 21239811.
5. Shah N, Shpall EJ. NK antibody therapy: KIR-ative intent. Blood 114(13):2567-8, 9/2009. PMID: 19779042.
6. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research 13(17):5133-5143, 9/2007. PMID: 17785568.

Book Chapters

1. Shah N, Avery TP, Fu W, Weber D, Lu G, Lin P, Qazilbash M, Wang M. Myeloma and Other Plasma Cell Dyscrasias. In: M. D. Anderson Manual of Medical Oncology, 2nd. Ed(s) James Shanahan and Cindy Yoo. The McGraw-Hill Companies: Houston, Texas, 245-282, 2011. ISBN: 978-0-07-170106-8.

Grant & Contract Support

Title: Investigation of Factors that Inflence the Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Functiional Capacity of Natural Killer (NK) cells and other CD16+ Effectors
Funding Source: CPRIT
Role: Collaborator
Principal Investigator: Rezvani
Duration: 12/1/2012 - 11/30/2015
 
Title: NK Adoptive Transfer and mAb Combination for Colon Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Katayoun Rezvani
Duration: 6/1/2012 - 5/30/2016

Last updated: 7/31/2014